DDInter1608 DDInter875
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences, [FDA label]. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL), however, has now been approved for a variety of conditions [FDA label]. On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab).
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Rituximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Rituximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Rituximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palifermin
Rituximab {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Rituximab {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Rituximab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Palifermin
Rituximab may lead to a major life threatening interaction when taken with Golimumab
Rituximab may lead to a major life threatening interaction when taken with Infliximab